Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY1 | P47900 | 6/20 | 0.57 |
| ▸ | P2RY2 | P41231 | 5/20 | 0.57 |
| ▸ | P2RY11 | Q96G91 | 1/20 | 0.57 |
| ▸ | P2RX3 | P56373 | 6/20 | 0.53 |
| ▸ | P2RX4 | Q99571 | 5/20 | 0.53 |
| ▸ | P2RX1 | P51575 | 4/20 | 0.53 |
| ▸ | P2RX2 | Q9UBL9 | 2/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | SRC | P12931 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | RNASEL | Q05823 | 1/20 | 0.48 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22990449 | 0.84 | P2RY1 (0.54) | P2RY1P2RY2P2RY11POLBSRC | |
| SCHEMBL15281794 | 0.83 | P2RY1 (0.57) | P2RY1P2RY2P2RY11P2RX3P2RX4 | |
| SCHEMBL20324651 | 0.78 | TAS1R3 (0.47) | P2RY1POLBALDH1A1 | |
| SCHEMBL25556583 | 0.78 | P2RY1 (0.58) | P2RY1P2RY2P2RY11P2RX3P2RX4 | |
| SCHEMBL16373878 | 0.78 | P2RX1 (0.61) | P2RY1P2RY2P2RY11P2RX3P2RX4 | |
| SCHEMBL15678094 | 0.78 | P2RY1 (0.59) | P2RY1P2RY2P2RY11P2RX3P2RX4 | |
| SCHEMBL21637015 | 0.77 | P2RY1 (0.53) | P2RY1P2RY2P2RY11P2RX3P2RX4 | |
| SCHEMBL25556577 | 0.77 | P2RY1 (0.56) | P2RY1P2RY2P2RY11P2RX3P2RX4 | |
| SCHEMBL16490110 | 0.77 | P2RX1 (0.57) | P2RY1P2RY2P2RY11P2RX3P2RX4 | |
| SCHEMBL16374061 | 0.77 | P2RY1 (0.58) | P2RY1P2RY2P2RY11P2RX3P2RX4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210179656-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | Janssen Biopharma, Inc. (US) | 2021-06-17 | — | — | US | disclosed |
| WO-2013096679-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | ALIOS BIOPHARMA, INC. (US) | 2013-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210179656-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | PNP, NT5C3B, ADAR | P2RY1 72/4885P2RY2 133/4885P2RY11 76/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.